Catalyst Biosciences to Present at the Annual BIO CEO &

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
12
Catalyst Biosciences to Present at the Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc., (Nasdaq: CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., president and chief executive officer, will present a corporate overview at the Annual BIO CEO & Investor Conference, being held in New York City on February 11-12, 2019.

Presentation Details Date:               Tuesday, February 12, 2019 Time:               1:15 p.m. Eastern Time Location:         New York Marriott Marquis

To schedule a meeting with the Catalyst Biosciences management team at this conference, please contact LifeSci Advisors .

About Catalyst Catalyst is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com .

Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statement of historical facts (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) are forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including, but not limited to, the risk that trials and studies may be delayed and may not have satisfactory outcomes, that human trials will not replicate the results from animal studies, that potential adverse effects may arise from the testing or use of the Company’s products, including the generation of antibodies, the risk that costs required to develop or manufacture the Company’s products will be higher than anticipated, competition and other factors that affect our ability to establish collaborations on commercially reasonable terms and other risks described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 and the Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2017, June 30, 2017, and September 30, 2017 along with other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contacts

Investors: Fletcher Payne, CFO Catalyst Biosciences, Inc. 1.650.871.0761 investors@catbio.com

Media: Josephine Belluardo, Ph.D. LifeSci Public Relations 1.646.751.4361 jo@lifescipublicrelations.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Modeling and Mental Health Join Forces for Wellness

Updated Category News Views 2

A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...

Continue Reading
XKL Delivers MediaLight for High-Speed Optical Transport

Updated Category News Views 5

Unpacking the MediaLight Launch Kicking off September, XKL is tossing its hat in the ring with the MediaLight Xponder and Muxponder systems. These aren't just any run-of-the-mill gizmos—nope, they're touted as top-of-the-line optical transport solutions. The talk of the town is their ability to dish out high-density 100G and 400G transport, and for geeks in the trade,...

Continue Reading
Intus Bio Secures $2.7M for Colorectal Cancer Test

Updated Category News Views 4

Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...

Continue Reading
SES Sells to AFC Industries: A Strategic M&A Move

Updated Category News Views 8

Nashville's Notable Deal in Industrial Supply On a muggy September day in Nashville, XLCS Partners announced it was at the helm of a noteworthy transaction—the sale of Signature Engineered Solutions (SES) to AFC Industries. Now, this isn't just another corporate shuffle; it's a calculated move in the gritty world of fastening and engineered solutions. The Nitty-Gritty...

Continue Reading
DCM Services Teams with AKUVO to Boost Estate Recoveries

Updated Category News Views 3

Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...

Continue Reading
BusyBee AI Revolutionizes Classroom Feedback Efficiency

Updated Category News Views 7

Grading Overhaul: BusyBee's Role in Education Here's a twist for the history books: Agilix Labs' BusyBee, a slick AI assistant built right into the Buzz platform on Amazon Bedrock, is kicking traditional grading methods to the curb. This little helper is grading close to a million K-12 student submissions every month, meticulously approved by real teachers. Quite the...

Continue Reading
Seismic Pharma Kicks Off Phase 3 Trial for Istaroxime

Updated Category News Views 4

Seismic Sets the Stage for a Medical Milestone From the heart of biotech in Durham, North Carolina, seismic waves ripple through the medical community as Seismic Pharmaceuticals embarks on a high-stakes adventure. It's official: they've enrolled their very first patient in the global Phase 3 trial of istaroxime, targeting the grim specter known as cardiogenic shock. You...

Continue Reading
Moore Law Investigates Aardvark Therapeutics' Risks

Updated Category News Views 2

Moore Law Launches Probe Into Aardvark Therapeutics Nobody likes stumbling across bad news over their morning coffee, but sometimes the market loves to keep you on your toes. Now it's Aardvark Therapeutics (NASDAQ: AARD) in the headlines, and not how they'd like. This time, Moore Law PLLC is rolling up its sleeves to dig into potential misconduct by the company's top...

Continue Reading
Step Inside Henson's Creature Shop Magic in NYC

Updated Category News Views 8

Unlock Puppet Magic with Jim Henson Tours Puppet fans, let me tell you, there's something going on in Queens, NY that's got both nostalgia and innovation scribbled all over it. We're talking about the legendary Jim Henson's Creature Shop opening its doors. If you're looking to relive the magic that helped shape a generation, get ready to dive into a world where creativity...

Continue Reading
QuickFi Nabs Top Finovate Award for Fourth Time

Updated Category News Views 4

An Unstoppable Force in Fintech Well, if QuickFi hasn't made a name for itself in fintech, then folks, I don't know what to tell you. This year, they’ve snagged yet another prestigious Finovate Award—this time for Best SMB/SME Banking Solution. That's not their first rodeo either; it’s the fourth time they’ve walked away winners. It's almost like they're...

Continue Reading

Top 5 Most Recently Viewed Articles

Associated Banc-Corp Sets Public Offering for Growth Funding

Updated Category News Views 208

Associated Banc-Corp Announces Stock Offering Associated Banc-Corp (NYSE: ASB) has recently made headlines with its announcement regarding a public offering of its common stock. The company is set to offer 12 million shares, each with a par value of $0.01, at a price of $25.00 per share. This means the total gross proceeds from this offering are expected to reach an...

Continue Reading
Understanding Hit-and-Run Consequences: Legal Insights

Updated Category News Views 301

Understanding the Serious Consequences of a Hit-and-Run Motor vehicle accidents are undoubtedly stressful situations. However, the decisions made in those critical moments after an accident can have significant legal consequences. In some regions, leaving the scene without fulfilling legal obligations is viewed as a criminal act, commonly known as a hit-and-run. The...

Continue Reading
Sola Secures $8 Million in Funding to Transform Insurance Industry

Updated Category News Views 98

Sola Secures Vital Funding for Innovative Insurance Solutions In an exciting development in the insurtech sector, Sola has closed an impressive $8 million in Series A funding, successfully increasing its total funding to $11.7 million. This latest financial boost was spearheaded by notable investors including FINTOP Capital and JAM FINTOP, with additional support from...

Continue Reading
Eastside Distilling Set to Reveal Q3 Results on Upcoming Call

Updated Category News Views 60

Eastside Distilling to Announce Third Quarter Financial Results Eastside Distilling, Inc. (NASDAQ: EAST), a consumer-oriented beverage company renowned for its craft alcoholic beverages, has scheduled the announcement of its third quarter financial results. The report will be released after the market closes, presenting exciting insights into the company’s performance...

Continue Reading
Discover Your Dream Home at The Meadows With Toll Brothers

Updated Category News Views 193

Toll Brothers Unveils Final Home Opportunities at The Meadows Introducing the last chance to own a luxurious residence in the coveted community of The Meadows, currently presented by Toll Brothers, Inc. As the leading builder of luxury homes in the nation, Toll Brothers invites homebuyers to seize this unique opportunity in a community that epitomizes Southern Californian...

Continue Reading